Breakthrough cancer pain in opioid-tolerant patient

Breakthrough cancer pain in opioid-tolerant patients refers to severe, transient exacerbations of pain that erupt over baseline persistent pain in individuals with oncologic disease

Breakthrough cancer pain in opioid-tolerant patients refers to severe, transient exacerbations of pain that erupt over baseline persistent pain in individuals with oncologic disease

This clinical state specifically affects oncology patients whose background pain is otherwise stably managed by around-the-clock, therapeutic opioid regimens, meeting clinical criteria for opioid tolerance (typically defined as receiving at least 60 mg of oral morphine equivalents daily for one week or longer) Clinically, they are distinguished from unmanaged baseline pain by their sudden onset, high intensity, and relatively short duration

This clinical state specifically affects oncology patients whose background pain is otherwise stably managed by around-the-clock, therapeutic opioid regimens, meeting clinical criteria for opioid tolerance (typically defined as receiving at least 60 mg of oral morphine equivalents daily for one week or longer)

This clinical state specifically affects oncology patients whose background pain is otherwise stably managed by around-the-clock, therapeutic opioid regimens, meeting clinical criteria for opioid tolerance (typically defined as receiving at least 60 mg of oral morphine equivalents daily for one week or longer) Clinically, they are distinguished from unmanaged baseline pain by their sudden onset, high intensity, and relatively short duration

Pathophysiologically driven by tumor invasion, neuropathic injury, visceral distension, or oncologic therapies, these acute episodes present either spontaneously or as incident pain provoked by movement

Pathophysiologically driven by tumor invasion, neuropathic injury, visceral distension, or oncologic therapies, these acute episodes present either spontaneously or as incident pain provoked by movement

Pathophysiologically driven by tumor invasion, neuropathic injury, visceral distension, or oncologic therapies, these acute episodes present either spontaneously or as incident pain provoked by movement Clinically, they are distinguished from unmanaged baseline pain by their sudden onset, high intensity, and relatively short duration